Antengene Corporation Ltd
HKEX:6996

Watchlist Manager
Antengene Corporation Ltd Logo
Antengene Corporation Ltd
HKEX:6996
Watchlist
Price: 3.88 HKD 1.84% Market Closed
Market Cap: 2.6B HKD

Net Margin
Antengene Corporation Ltd

-347.2%
Current
-788%
Average
4.9%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-347.2%
=
Net Income
-319.3m
/
Revenue
92m

Net Margin Across Competitors

Antengene Corporation Ltd
Glance View

Market Cap
2.6B HKD
Industry
Pharmaceuticals

Antengene Corp. Ltd. operates as clinical-stage Asia-Pacific biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-11-20. The firm is principally engaged in the discovery, development, manufacturing and commercialization of biotech products. The Company’s products include ATG-010 (selinexor), treating for relapsed/refractory multiple myeloma, relapsed/refractory diffuse large B-cell lymphoma and non-small cell lung cancer and ATG-008 (onatasertib), treating for hepatocellular carcinoma and non-small cell lung cancer. The firm mainly conducts its business in Asia-Pacific.

Intrinsic Value
2.08 HKD
Overvaluation 46%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-347.2%
=
Net Income
-319.3m
/
Revenue
92m
What is the Net Margin of Antengene Corporation Ltd?

Based on Antengene Corporation Ltd's most recent financial statements, the company has Net Margin of -347.2%.

Back to Top